The Special Committee of Seer’s Board of Directors has unanimously rejected recent unsolicited, non-binding acquisition proposals for the company. The board determined that offers including a $2.55 per share cash price plus contingent value rights from the Radoff-JEC Group and a $2.45 per share offer from CEO Omid Farokhzad fail to reflect Seer’s intrinsic value. Consequently, Seer will remain an independent public company rather than pursuing a sale at this time. The company operates in the biotechnology sector, providing deep proteomic insights through its proprietary Proteograph product suite.
